Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer.
Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer.
复制标题
肿瘤B7-H3（CD276）胰腺癌的表达和存活率。
DOI：
10.3390/jcm7070172
复制
发表时间：
2018-07-10
影响因子：
3.9
通讯作者：
Ishikawa Y
中科院分区：
文献类型：
--
作者：
Inamura K;Takazawa Y;Inoue Y;Yokouchi Y;Kobayashi M;Saiura A;Shibutani T;Ishikawa Y
B7-H3(CD276)是免疫调节剂家族中的一员，负责协调抗肿瘤免疫。到目前为止，只有小规模的研究检验了B7-H3的表达与胰腺癌患者生存的关系，得出了不确定的结果。我们用免疫组织化学方法检测了150例胰腺导管腺癌患者肿瘤组织中B7-H3的表达。在15 0例胰腺癌中，99例(66%)B7-H3表达阳性(≥10%肿瘤细胞)。我们根据B7-H3的表达将肿瘤分为四组(阴性、低、中和高)，发现高B7-H3表达与较低的无病生存率(DFS)独立相关；B7-H3高表达与阴性B7-H3表达的多变量风险比(HR)=3.12；95%可信区间(CI)=1.48-6.15；P趋势=0.0026。此外，B7-H3的表达与生存的关系因病理分期(p期)而异(P交互作用=0.048，p期I-II和P-IV之间)。P期I~II期(多变量HR=3.1 0，95%CI=1.75~5.69；P<；0.0001)与P期III~IV期(多变量HR=1.2 0，95%CI=0.67~2.2 8；P=0.5 5)相比，B7-H3阳性表达与DFS降低的相关性更强。在胰腺癌患者中，肿瘤高表达B7-H3独立地与低生存率相关，并且这种相关性在p期I-II期肿瘤中比在P期III-IV期肿瘤中更强。B7-H3表达可能是识别侵袭性早期胰腺癌的有用的预后生物标志物。
B7-H3 (CD276), a member of the family of immune modulators, orchestrates antitumor immunity. To date, only small-sized studies have examined the association of B7-H3 expression with survival in pancreatic cancer, yielding inconclusive results. We evaluated tumor B7-H3 expression in 150 consecutive patients with pancreatic ductal adenocarcinoma using immunohistochemistry. B7-H3 expression was positive (≥10% tumor cells) in 99 of 150 (66%) cases of pancreatic cancer. We classified the tumors into four groups depending on B7-H3 expression (negative, low, intermediate, and high) and found that higher B7-H3 expression was independently associated with lower disease-free survival (DFS; for high vs. negative B7-H3 expression: multivariable hazard ratio (HR) = 3.12; 95% confidence interval (CI) = 1.48–6.15; Ptrend = 0.0026). Furthermore, the association of B7-H3 expression with survival differed according to the pathological stage (p-stage) (Pinteraction = 0.048, between p-stages I–II and III–IV). The association of B7-H3 positivity with lower DFS was stronger in tumors with p-stage I–II (multivariable HR = 3.10, 95% CI = 1.75–5.69; P < 0.0001) than in those with p-stage III–IV (multivariable HR = 1.20, 95% CI = 0.67–2.28; P = 0.55). We demonstrated that tumor high B7-H3 expression is independently associated with poor survival in patients with pancreatic cancer and that this association is stronger in tumors with p-stage I–II than in those with p-stage III–IV. B7-H3 expression may be a useful prognostic biomarker for identifying aggressive early-stage pancreatic cancer.
登录
查看更多内容
影响因子：
--
作者：
Li D;Wang J;Zhou J;Zhan S;Huang Y;Wang F;Zhang Z;Zhu D;Zhao H;Li D;Chen G;Zhu X;Zhao X
通讯作者：
Zhao X
影响因子：
7
作者：
Vonderheide RH;Bayne LJ
通讯作者：
Bayne LJ
共刺激分子B7-H1、B7-H3、B7-H4在人胰腺癌中的共表达及其临床意义
影响因子：
4
作者：
Chen Y;Sun J;Zhao H;Zhu D;Zhi Q;Song S;Zhang L;He S;Kuang Y;Zhang Z;Li D
通讯作者：
Li D
影响因子：
4.4
作者：
Sun, MY;Richards, S;Dong, C
通讯作者：
Dong, C
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM